Chugai Pharmaceutical Co. released data showing Enspryng had a favorable benefit-risk profile and effectively reduced relapses over 4 years of treatment among people with a form of neuromyelitis optica spectrum disorder.
The treatment is a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody. Data on its efficacy and safety from open-label extension periods of two studies, as well as results from an additional study, was presented at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
“The data show that the efficacy and safety of